Patent details

300816 Product Name: Alemtuzumab

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300816
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2066352
Status:
Refused Art. 10 of the EC Regulations
Application number:
300816
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/13/869
Marketing Authorization Type:
EEA
Marketing Authorization Date:
16/09/2013
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
31/05/2016
First Marketing Authorization date:
16/09/2013
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
03/06/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
21/10/2020

Applicant/holder

From:
03/06/2016
 
 

 

Name:
Genzyme Corporation
Address:
500 Kendall Street, 02142, Cambridge, Massachusetts, United States of America (US)

From:
03/06/2016
 
 

 

Name:
Alcafleu Management GmbH & Co. KG
Address:
Lilienthalstrasse 4, 12529 Schönefeld OT Waltersdorf, Germany (DE)

Agent

Name:
ir. H.A. Witmans c.s.
From:
03/06/2016
Address:
V.O. Postbus 87930, 2508 DH, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
43/20
Publication date:
21/10/2020
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
23/16
Publication date:
10/06/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
21/10/2020 Outgoing Correspondence Decision refusal 2 PDF /9/3/1/2/6/0800062139/docs/300816_11_373615l527a.pdf
13/07/2020 Outgoing Correspondence Letter to applicant 2 PDF /9/3/1/2/6/0800062139/docs/300816_2_353798l173.pdf
14/10/2016 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /9/3/1/2/6/0800062139/docs/300816_1_incomingcorrespondencepaper20161017030148231.pdf
14/10/2016 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /9/3/1/2/6/0800062139/docs/300816_3_incomingcorrespondencepaper20161017030148161.pdf
13/10/2016 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /9/3/1/2/6/0800062139/docs/300816_9_incomingcorrespondencepaper20161014031428956.pdf
14/07/2016 Outgoing Correspondence Outgoing Letter 16 PDF /9/3/1/2/6/0800062139/docs/300816_8_outgoingcorrespondence20200415095841417.pdf
07/06/2016 Outgoing Correspondence Outgoing Letter 1 PDF /9/3/1/2/6/0800062139/docs/300816_4_60659l174.pdf
01/06/2016 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /9/3/1/2/6/0800062139/docs/300816_0_incomingcorrespondencepaper20160603031039086.pdf
01/06/2016 SPC Documents Annex SPC 4 PDF /9/3/1/2/6/0800062139/docs/300816_5_supplprotectioncertificate20210330050856967.pdf
01/06/2016 Application Form First filed application form 3 PDF /9/3/1/2/6/0800062139/docs/300816_6_applicationform20160603031038983.pdf
01/06/2016 SPC Documents Annex SPC 18 PDF /9/3/1/2/6/0800062139/docs/300816_7_supplprotectioncertificate20210330050857052.pdf
01/06/2016 SPC Documents Summary of the characteristics of the product 20 PDF /9/3/1/2/6/0800062139/docs/300816_10_supplprotectioncertificate20210330050856885.pdf
01/06/2016 SPC Documents Marketing Authorization SPC 3 PDF /9/3/1/2/6/0800062139/docs/300816_12_supplprotectioncertificate20160603031039149.pdf